Business
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025.
About this update from Metavia Inc.
CAMBRIDGE, Mass. , Oct. 14, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will also participate in one-on-one meetings. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. To schedule a meeting with management outside of the conference, investors can contact Michael Miller at [email protected] . About MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin ( OXM ) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor ( GCGR ) dual agonist . OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR , thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists . In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1 , GIP , and PYY . In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis , hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit www.metaviatx.com . Contacts: MetaVia Marshall H. Woodworth Chief Financial Officer +1-857-299-1033 [email protected] Rx Communications Group Michael Miller +1-917-633-6086 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/metavia-to-present-at-the-hc-wainwright-liver-disease-virtual-conference-302582872.html